Oh my, you mean R&D in ground breaking technology actually requires expenditure? Well I never? Now why don't you be a good boy and show us all other comparable late stage phase 3 stem cell company's likely forward expenditure for accurate perspective?
I see as well as being a big brave boy and attacking me with insults online, and yet again, as you do so often to so many, you fail to have the proverbials to tag the victims of your insults.
Ann: Two-Year Results of Phase 1 SR-aGvHD Trial Presented at ISCT, page-26
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $36.15M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.5¢ | 16.0¢ | $62.06K | 386.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 70000 | 2 |
View Market Depth
| Last trade - 14.47pm 25/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |